TargetMol

Carvedilol phosphate hemihydrate

Product Code:
 
TAR-T0342
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T0342-25mg25mg£95.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0342-50mg50mg£103.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0342-100mg100mg£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0342-200mg200mg£124.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0342-500mg500mg£142.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Carvedilol Phosphate is the phosphate salt form of carvedilol, a racemic mixture and adrenergic blocking agent with antihypertensive activity and devoid of intrinsic sympathomimetic activity.
CAS:
610309-89-2
Formula:
C48H60N4O17P2
Molecular Weight:
1026.967
Pathway:
Cytoskeletal Signaling; Neuroscience; Angiogenesis; Membrane transporter/Ion channel; ; Autophagy; Tyrosine Kinase/Adaptors; GPCR/G Protein; Metabolism
Purity:
1
SMILES:
O.OP(O)(O)=O.OP(O)(O)=O.COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12.COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12
Target:
VEGFR; Potassium Channel; LDL; Integrin; Gap Junction Protein; NADPH; Adrenergic Receptor; Autophagy

References

1. Nichols AJ, et al. Fundam Clin Pharmacol. 1991;5(1):25-38.